Wockhardt Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: May 15, 2018
Pages: 50
US$ 499.00
Wockhardt Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: W89827E2762BEN

Download PDF Leaflet

Wockhardt Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Wockhardt Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Wockhardt Ltd. and its competitors. This provides our Clients with a clear understanding of Wockhardt Ltd. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Wockhardt Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Wockhardt Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Wockhardt Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Wockhardt Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Wockhardt Ltd. business.

About Wockhardt Ltd.

Wockhardt Limited operates as a research and technology oriented pharmaceutical company that manufactures and markets pharmaceutical products. The Company's subsidiaries include Wockhardt Europe Limited, Wockhardt Biopharm Limited, Consolidated Wallis Group Limited, Island Company Limited and CP Pharmaceuticals (Holdings) Limited.

The company has developed major brands in Anti-infectives, Pain & Inflammation, Cough, Psychiatry, Medical nutrition and Biotechnology segments. Wockhardt has developed expertise in various facets of recombinant biotechnology - cloning of genes, development of production strains, capability in all major expression systems (yeast, mammalian and bacterial cells), purification and downstream processing, and formulation.

Wockhardt's R&D programs involves in Biotechnology and bio-pharmaceuticals; New Drug Discovery; Pharmaceutical formulations development including Novel Drug Delivery Systems; Innovative process development for Bulk Actives using chemical, fermentation and peptide synthesis technologies; Development of new medical nutrition products; Clinical research including Pharmacology, Toxicology and Pharmacokinetics and Pharmacodynamics and Agrochemicals and bio-agro product.

Pharmaceutical Research: Wockhardt's pharmaceutical formulation development concentrates substantially on developing products based on its patented Novel Drug Delivery Systems. The Company's products are under various stages of development in the areas of cardiology, gastroenterology, neurology, endocrinology and allergy.

Bulk Activities: Wockhardt has research and manufacturing capabilities in all major routes of bulk active synthesis including chemical, fermentation and peptide synthesis.

Biotechnology: The Company's in-house biotechnology team has developed recombinant Erythropoeitin. The Company's other products under development include Human insulin (diabecology), Interferon alpha 2B and other anti-cancer drugs.

Peptide Research: Wockhardt's R&D is active in developing various bulk actives using peptide synthesis technologies. These include several anti-cancer and gynaecology drugs.

Business Divisions

International Pharmaceuticals: The Company has Joint venture with Ranbaxy, Inc. for the U.S. market. The Company's international products pipeline includes: Bulk Actives, Novel Drug Delivery System products and off patent generic formulations. The Company's U.S. FDA approved ANDAs include Captopril, Ranitidine, Niacin, Enalapril, Famotidine. Its U.S. FDA approved injectable facility produces cartridges, vials m, ampoules and free-dried products.

Domestic Pharmaceuticals: The Company's Domestic drugs include Pain and Inflamation Drugs, Corticosterioids, Anti-Infectives, Cough preparations (Zedex, Bro-Zedex, Alpha-Zedex), Vitamins and Nutrients, Recombinant Insulin (Wosulin), Vaccines (Biovac-B), and Erythropoietin (Wepox).

Medical Nutrition

Paediatric Nutrition: Paediatric Nutrition consists of general purpose breast milk supplements such as Dexolac 1 and Dexolac 2, as well as specialized nutrition for conditions such as lactose intolerance-Nusobee and Nusobee-18. Dexolac SC is a special nutrient for premature and low birth weight infants.

Enteral & Clinical Nutrition

Clinical Nutritions include general purpose tube-feed supplements used in nasogastric feeding and disease-specific formulations for hospitalized as well as ambulatory patients. Its product range includes Recupex, general purpose enteral nutrition; Nutrocal, general purpose enteral nutrition; Nutrocal-DM, used for diabetics; Nutrenal, used for acute renal failure patients on dialysis; Nutrenal-CRF, used for chronic renal failure patients; Nutriprot, a high protein product for patients suffering from cancer, TB; First Food range; Grow Up a nutritional supplement for Children.

Animal Health

The Company's Animal Health Business covers both large animals (cattle, sheep, camel, horses etc.) and poultry. The Company’s major therapeutic groups include feed supplements, antibiotics, anthelmintics and tonics. The Company's Animal Health products range covers Antibiotics, Antibacterials, Anthelmintics, Tonics, Feed Supplements, Coccidiostats and Multivitamins.

Health Care

Wockhardt Hospitals offer a host of specialized health check-up packages including general health management, comprehensive heart check-up, senior citizens’ profile, women and children’s health check-up programmes. Wockhardt Medical & Research Centre, at Calcutta provides hi-tech 'Day Care' in urology, gastro-enterology and ophthalmology. Wockhardt Hospitals at Mulund, Mumbai is a five-hospital complex comprising: Wockhardt Heart Hospital, Wockhardt Brain & Spine Hospital, Wockhardt Bone & Joint Hospital, Wockhardt Eye Hospital, and Wockhardt Minimal Access Surgery Hospital. Wockhardt Hospital & Heart Institute at Bangalore provides its services to cardiology and cardio thoracic surgery.

The company has launched Nicopatch, a generic transdermal nicotine patch that delivers a steady dose of nicotine over 24 hours, in the UK.


Wockhardt Limited was incorporated in 1999.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Wockhardt Ltd. Direct Competitors
5.2. Comparison of Wockhardt Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Wockhardt Ltd. and Direct Competitors Stock Charts
5.4. Wockhardt Ltd. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Wockhardt Ltd. Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Wockhardt Ltd. Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Wockhardt Ltd. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Wockhardt Ltd. Major Shareholders
Wockhardt Ltd. History
Wockhardt Ltd. Products
Revenues by Segment
Revenues by Region
Wockhardt Ltd. Offices and Representations
Wockhardt Ltd. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Wockhardt Ltd. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Wockhardt Ltd. Capital Market Snapshot
Wockhardt Ltd. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Wockhardt Ltd. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Wockhardt Ltd. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Wockhardt Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Wockhardt Ltd. 1-year Stock Charts
Wockhardt Ltd. 5-year Stock Charts
Wockhardt Ltd. vs. Main Indexes 1-year Stock Chart
Wockhardt Ltd. vs. Direct Competitors 1-year Stock Charts
Wockhardt Ltd. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

Wockhardt Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: